Literature DB >> 20870446

[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.

Pekka Jokinen1, Noora Scheinin, Sargo Aalto, Kjell Någren, Nina Savisto, Riitta Parkkola, Johanna Rokka, Merja Haaparanta, Matias Röyttä, Juha O Rinne.   

Abstract

The objective of this study was to identify possible group differences between PD patients with dementia and without dementia by combining different functional and structural imaging methods in vivo, which might provide an opportunity to disentangle the pathophysiological correlates of cognitive impairment and dementia in PD. We performed a neuropsychological evaluation, structural brain MRI, [(18)F]FDG PET and [(11)C]PIB PET in 19 PD patients [eight non-demented (PD), eleven demented (PDD)] and 24 healthy elderly volunteers. [(11)C]PIB region-to-cerebellum ratios did not differ significantly between the groups in any brain region (p > 0.05). PDD patients showed impaired glucose metabolism in cortical brain regions and this reduction was associated with the degree of cognitive impairment. PDD patients had more atrophy both in the hippocampus and the frontal cortex compared with PD patients and controls, and hippocampal atrophy was associated with impaired memory. This cross-sectional data suggests that development of dementia in PD is associated with extensive spread of hypometabolism beyond the occipital cortex, and with hippocampal and frontal atrophy but not beta-amyloid deposition consistent with a unique biological process related to PD rather than co-incidental development of AD in persons with PD.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870446     DOI: 10.1016/j.parkreldis.2010.08.021

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  30 in total

1.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 2.  Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

Authors:  Myria Petrou; Ben A Dwamena; Bradley R Foerster; Mark P MacEachern; Nicolaas I Bohnen; Martijn Ltm Müller; Roger L Albin; Kirk A Frey
Journal:  Mov Disord       Date:  2015-04-16       Impact factor: 10.338

Review 3.  The relationship between atrophy and hypometabolism: is it regionally dependent in dementias?

Authors:  María C Rodriguez-Oroz; Belen Gago; Pedro Clavero; Manuel Delgado-Alvarado; David Garcia-Garcia; Haritz Jimenez-Urbieta
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 4.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

5.  Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes.

Authors:  Kirk A Frey; Myria Petrou
Journal:  Clin Transl Imaging       Date:  2015-02-01

Review 6.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 7.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

8.  Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-29       Impact factor: 3.575

Review 9.  Lewy body dementias.

Authors:  Zuzana Walker; Katherine L Possin; Bradley F Boeve; Dag Aarsland
Journal:  Lancet       Date:  2015-10-24       Impact factor: 79.321

Review 10.  Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.

Authors:  Stephen N Gomperts
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.